Processa Pharmaceuticals, Inc.
General ticker "PCSA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.8M (TTM average)
Processa Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -13.4%.
Estimated limits based on current volatility of 3.4%: low 3.35$, high 3.72$
Factors to consider:
- Total employees count: 13 (-13.3%) as of 2023
- Top business risk factors: Liquidity and credit risks, Product quality issues, Patent risks, Management challenges, Cybersecurity threats
- Current price 43.6% below estimated low
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [12.22$, 41.45$]
- 2025-12-31 to 2026-12-31 estimated range: [6.27$, 22.12$]
Financial Metrics affecting the PCSA estimates:
- Negative: with PPE of -5.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -407.57 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: -0.76 < Inventory ratio change, % of 0
- Positive: Investing cash flow per share per price, % of -0.12 > -0.62
- Negative: negative Industry operating income (median)
Short-term PCSA quotes
Long-term PCSA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $27.53MM | $11.46MM | $12.05MM |
| Operating Income | $-27.53MM | $-11.46MM | $-12.05MM |
| Non-Operating Income | $0.10MM | $0.34MM | $0.20MM |
| R&D Expense | $11.49MM | $5.80MM | $7.27MM |
| Income(Loss) | $-27.42MM | $-11.12MM | $-11.85MM |
| Profit(Loss)* | $-27.42MM | $-11.12MM | $-11.85MM |
| Stockholders Equity | $7.47MM | $4.99MM | $1.70MM |
| Assets | $8.62MM | $5.79MM | $3.23MM |
| Operating Cash Flow | $-9.61MM | $-8.06MM | $-11.25MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $0.00MM | $-0.00MM | $-0.00MM |
| Financing Cash Flow | $-0.39MM | $6.27MM | $7.73MM |
| Earnings Per Share** | $-851.18 | $-211.99 | $-96.82 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.